<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>ESAIC/ESRA guidelines for management related to anticoagulation for high bleeding risk blocks (neuraxial and deep nerve blocks)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">ESAIC/ESRA guidelines for management related to anticoagulation for high bleeding risk blocks (neuraxial and deep nerve blocks)</h1>
<div class="graphic"><div class="figure"><div class="ttl">ESAIC/ESRA guidelines for management related to anticoagulation for high bleeding risk blocks (neuraxial and deep nerve blocks)</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Drug and dose</td> <td class="subtitle1" colspan="3">High risk of bleeding block (neuraxial and deep nerve blocks)</td> </tr> <tr> <td class="subtitle2">Time from last drug intake to intervention</td> <td class="subtitle2">Target laboratory value at intervention</td> <td class="subtitle2">Time from intervention to next drug dose</td> </tr> <tr> <td>VKA</td> <td>Until target laboratory value: (about 3 days acenocoumarol; 5 days warfarin, fluindione; 7 days phenprocoumon)</td> <td>INR normal</td> <td> </td> </tr> <tr> <td>DXA low*</td> <td>24 hours rivaroxaban, edoxaban (30 hours if CrCl &lt;30 mL/minute), 36 hours apixaban</td> <td>No testing</td> <td> </td> </tr> <tr> <td>DXA high</td> <td>72 hours or until target laboratory value (until target laboratory value if CrCl &lt;30 mL/minute)</td> <td>DXA level &lt;30 ng/mL (alternative: ≤0.1 anti-Xa international units/mL)</td> <td>Low doses: according to guidelines on postoperative VTE prophylaxis<sup>¶</sup> (about 8 hours − t<sub>max</sub> = 6 hours postoperative). Consider prolonged time interval after bloody tap.<sup>Δ</sup></td> </tr> <tr> <td>Dabigatran low*</td> <td>48 hours</td> <td>No testing</td> <td> </td> </tr> <tr> <td>Dabigatran high</td> <td>72 hours or until target laboratory value (until target laboratory value if CrCl &lt;50 mL/minute)</td> <td>DTI level &lt;30 ng/mL (alternative: thrombin time in normal range of local laboratory)</td> <td>High doses: according to guidelines on therapeutic anticoagulation<sup>◊</sup> (about 24 hours postoperative).</td> </tr> <tr> <td> <p>LMWH low</p> <p class="extra_spacing_top indent1">≤50 anti-Xa international units/kg/day</p> <p class="extra_spacing_top indent1">Enoxaparin ≤40 mg/day</p> </td> <td>12 hours (24 hours if CrCl &lt;30 mL/minute)</td> <td>No testing</td> <td> </td> </tr> <tr> <td>LMWH high</td> <td>24 hours (48 hours if CrCl &lt;30 mL/minute) or until target laboratory value (especially if CrCl &lt;30 mL/minute)</td> <td>≤0.1 anti-Xa international units/mL</td> <td>VKA, DOAC, LMWH high, UFH high; should not be administered with a catheter in situ.</td> </tr> <tr> <td> <p>UFH low</p> <p class="extra_spacing_top indent1">≤200 international units/kg/day SC</p> <p class="extra_spacing_top indent1">≤100 international units/kg/day IV</p> </td> <td>4 hours</td> <td>No testing</td> <td>UFH low: 1 hour for IV in cardiovascular surgery.</td> </tr> <tr> <td>UFH high</td> <td>Until target laboratory value (about 6 hours if IV, 12 hours if SC)</td> <td>aPTT or anti-Xa or ACT in normal range of local laboratory</td> <td> </td> </tr> <tr> <td> <p>Fondaparinux low</p> <p class="extra_spacing_top indent1">≤2.5 mg/day</p> </td> <td>36 hours (72 hours if CrCl &lt;50 mL/minute)</td> <td>No testing</td> <td> </td> </tr> <tr> <td>Fondaparinux high</td> <td>Until target laboratory value (about 4 days)</td> <td>Calibrated ≤0.1 anti-Xa international units/mL</td> <td> </td> </tr> <tr> <td> <p>Aspirin low</p> <p class="extra_spacing_top indent1">≤200 mg/day</p> </td> <td>0</td> <td>No testing</td> <td>Routinely prescribed next time point.</td> </tr> <tr> <td>Aspirin high</td> <td>3 days (in normal platelet counts) to 7 days</td> <td>(Consider specific platelet function tests in normal range of local laboratory)</td> <td>6 hours.</td> </tr> <tr> <td>P2Y<sub>12</sub> inhibitor</td> <td>5 days ticagrelor; 5 to 7 days clopidogrel; 7 days prasugrel; or until target laboratory value</td> <td> </td> <td>0-hours clopidogrel 75 mg; 24 hours prasugrel, ticagrelor; 2 days clopidogrel 300 mg.</td> </tr> <tr> <td>Aspirin low + anticoagulant</td> <td>Aspirin: 0 + time interval of specific anticoagulant</td> <td>Specific laboratory test for combined anticoagulant</td> <td> <p>Aspirin low: routinely prescribed next time point.</p> <p>Combined anticoagulant, antiplatelet drug: according to guidelines on therapeutic anticoagulation, platelet inhibition<sup>◊</sup> (about 24 hours postoperative).</p> </td> </tr> <tr> <td>Aspirin low + antiplatelet drug</td> <td>Aspirin: 0 + time interval of specific antiplatelet drug</td> <td>(Consider specific laboratory test for combined antiplatelet drug)</td> <td> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>ESAIC: European Society of Anaesthesiology and Intensive Care; ESRA: European Society of Regional Anaesthesia; VKA: vitamin K agonist; INR: international normalized ratio; DXA: direct Xa agonist; CrCl: creatinine clearance; VTE: venous thromboembolism; DTI: direct thrombin inhibitor; LMWH: low molecular weight heparin; DOAC: direct-acting oral anticoagulants; UFH: unfractionated heparin; IV: intravenous; SC: subcutaneous; aPTT: activated partial thromboplastin time; ACT: activated clotting time; EHRA: European Heart Rhythm Association.</p>
* Definitions of low and high DOAC doses:
<ul>
<li>Rivaroxaban – Low dose is defined as 2.5 mg twice daily or 10 mg once daily; high dose as 15 mg twice daily or 20 mg once daily when used for VTE treatment or atrial fibrillation. When used for extended thromboprophylaxis, 20 mg once daily is considered low dose.</li>
<li>Apixaban – Low dose is defined as 2.5 mg twice daily (as long as certain criteria are absent, such as age ≥80 years, body weight &lt;60 kg, or chronic kidney impairment), and high dose as 5 or 10 mg twice daily.</li>
<li>Dabigatran – Low dose is defined as 220 mg once daily, or 150 mg once daily if CrCl is 30 to 50 mL/minute or age ≥75); high dose is defined as 150 mg twice daily, or 110 or 150 mg twice daily if CrCl is &lt;50 mL/minute or age 75 to 80, or 110 mg twice daily if age ≥80.</li>
</ul>
<p class="extra_spacing_top">¶ For example, ESAIC guidelines on VTE prophylaxis.<sup>[1,2]</sup></p>
<p class="extra_spacing">Δ Blood in the needle/catheter.</p>
◊ For example, EHRA guidelines.<sup>[3]</sup></div><div class="graphic_reference">References:
<ol>
<li>Afshari A, Ageno W, Ahmed A, et al. European Guidelines on perioperative venous thromboembolism prophylaxis: executive summary. Eur J Anaesthesiol 2018; 35:77.</li>
<li>Samama CM, Afshari A. European guidelines on perioperative venous thromboembolism prophylaxis. Eur J Anaesthesiol 2018; 35:73.</li>
<li>Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. EP Europace 2018; 20:1231.</li>
</ol>
<p class="extra_spacing_top">From: Kietaibl S, Ferrandis R, Godier A, et al. Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines. Eur J Anaesthesiol 2022; 39:100. DOI: <a href="https://journals.lww.com/ejanaesthesiology/Fulltext/2022/02000/Regional_anaesthesia_in_patients_on_antithrombotic.4.aspx" target="_blank">10.1097/EJA.0000000000001600</a>. Copyright © 2022 European Society of Anaesthesiology and Intensive Care. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</p></div><div id="graphicVersion">Graphic 138528 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
